Thursday, March 17, 2011

Despite Budget Cuts, Layoff Fears, Milwaukee Teachers Fight for Taxpayer-Funded Viagra







With the district in a financial crisis and hundreds of its members facing layoffs, the Milwaukee teachers union is taking a peculiar stand: fighting to get their taxpayer-funded Viagra back.



The union has asked a judge to order the school board to again include Pfizer Inc.'s erectile dysfunction drug and similar pills in its health insurance plans.



The filing is the latest in a two-year legal campaign in which the union has argued, so far unsuccessfully, that the board's policy of excluding erectile dysfunction drugs discriminates against male employees. The union says Viagra, Cialis, Levitra and others are necessary treatment for "an exclusively gender-related condition."



But lawyers for the school board say the drugs were excluded in 2005 to save money, and there is no discrimination because they are used primarily for recreational sex and not out of medical necessity.



The filing last month comes as the union, the Milwaukee Teachers' Education Association, is also protesting hundreds of layoff notices issued to teachers for the coming school year. Citing a "financial crisis" caused by exploding benefit costs and revenue shortfalls, the district's outgoing superintendent proposed laying off 682 employees in April.



The district gave layoff notices to 482 teachers in June, but recalled 89 of them last month. Additional teachers may be called back, but these are still the first layoffs of Milwaukee teachers in decades.



At least one lawmaker questioned why the union is fighting for Viagra while teachers are losing their jobs. A consultant for the school board has estimated that reinstating the drug benefit would cost $786,000 per year — the cost to keep perhaps a dozen first-year teachers employed.



State Rep. Jason Fields argues that the money could be better spent any number of ways — including saving jobs.



"You've got to be kidding me," said Fields, a Milwaukee Democrat. "The fact that is the point of contention is kind of frightening. What are our priorities? I'm all for love and peace. But almost 1 million dollars? And you go to court over this issue?"



Union spokeswoman Kris Collett declined comment. But its lawyer Barbara Quindel said the case was worth fighting despite the district's grim finances. Quindel said erectile dysfunction is associated with heart disease, prostate cancer and other conditions, and the drugs are approved by the Food and Drug Administration and recommended by the American Urological Association.



"MTEA believes that men should not be discriminated against in receiving treatment for their medical conditions," she said.



The union has argued the costs are tiny compared to the $1.3 billion annual budget. But the school board says they are "particularly burdensome" when it is under pressure to reduce benefit costs.



That the pills — which can cost $20 apiece without insurance — were included in the first place is somewhat unusual. Health insurer Aetna Inc., which provides one of the district's two plans, says its standard pharmacy plans exclude Viagra and other "drugs for lifestyle enhancement or performance."



Basic state employee health plans also generally don't cover those drugs, but more expensive premium plans might, said Dick Cauchi, who tracks health benefits at the National Conference of State Legislatures. Lisa Soronen, National School Boards Association senior staff attorney, also said she had never heard of a similar case or an example of a union negotiating coverage for erectile dysfunction drugs.



"If you are getting down to what drugs are covered, you are really getting in the weeds," she said, explaining most negotiations are over premiums and co-payments.



Board and union negotiators reached a deal in 2002 to cover six tablets per month for erectile dysfunction drugs in health plans that insure 10,000 employees, dependents and retirees. They quickly became popular.



By 2004, the number of claimants receiving prescriptions skyrocketed to more than 1,000 per year, costing the district $207,000. During negotiations in 2005, the board proposed eliminating the benefit and an arbitrator adopted the plan.



The union in 2008 filed a sex discrimination complaint with the state. In June, the Labor and Industry Review Commission ruled the union couldn't pursue the case without identifying employees who have been injured by the policy and the complaint was filed after the statute of limitations expired.



The union is asking a Milwaukee County Circuit Court judge to overturn that decision and declare the policy violates the Wisconsin Fair Employment Act. A ruling isn't expected for months.



Viagra is usually on the other side in discrimination cases. In recent years, several lawsuits have claimed that employer health plans discriminate against women when they cover Viagra but not contraceptives or infertility treatment.



But the Milwaukee union says males are treated unfairly here. In one brief, its lawyers argued that vaginal cream, anti-bacterial medicine and estrogen replacement medication for female sexual dysfunction are covered. Other options such as penile pumps and implants included in the plans "are far less desirable than oral medication," the filing said.



District spokesman Philip Harris said school officials won't comment because "we just want to leave it alone." But Miriam Horwitz, an attorney representing the board, argued in court filings the drugs weren't necessary to treat life-threatening disease or have children.

Boehringer Pulls the Plug on 'Pink Viagra'


FRANKFURTGermandrugmakerBoehringerIngelheimhasstoppeddevelopingadrugdubbedthe"pinkViagra"afterfailingtoconvinceU.S.regulatorstheexperimentalpillcouldboostwomen'ssexdrive.



"Thedecisionwasnotmadelightly,consideringtheadvancedstageofdevelopment,"chiefexecutiveAndreasBarnersaidonFridayofthehoped-formoneyspinneraimedatpremenopausalwomenwithapersistentandunexplainedlackofsexdrive.



Boehringer'smovemarkedthefailureofthelatestattempttofindafemalecounterparttoPfizer'sViagra,theblockbusterbluepillformen.Drugmakershavetestedvariouswaystoboostfemalelibido,butwomen'ssexliveshaveproveddifficulttotargetwithmedication.



U.S.governmentadviserssaidinJunethatBoehringer'spinkpill,basedontheactiveingredientflibanserin,offeredlittlehelptowomenandhadunacceptablerisks;nearly15percentofwomenstoppedtakingapillbeforeastudyendedduetosideeffectsincludingdepression,faintingandfatigue.



ThatledtheU.S.FoodandDrugAdministrationtoaskunlistedBoehringerinAugustformoreinformationonflibanserin,whichwouldhavebeenmarketedasGirosa.



"Theresponseoftheauthoritiesandthecomplexityandextentoffurtherquestionsthatwouldneedtobeaddressedtopotentiallyobtainregistrationforflibanserinhaveimpactedthecompany'sdecisiontofocusonotherpipelineprojects,"Boehringersaid.



Drugmakershavebeensearchingforamedicinetoimprovewomen'ssexlivessinceViagra'sdebut12yearsago.Themarketfora"pinkViagra"couldstretchintothebillionsofdollars.



NOMEDICINEFORLIBIDO



Originallydevelopedasanantidepressant,flibanserinwasbelievedtoactonbrainchemicalsthatplayaroleinsexualresponse.But,intrials,womenontheonce-a-daypill,takenatbedtimereportedunwantedsideeffects.



AnFDAadvisorycommitteevoted11-0inJunethatthedrug'srisksandbenefitswereunacceptableand10-1thateffectivenessdatawaslacking.



Boehringer,a125-year-oldcompanycontrolledbygreat-grandchildrenofthecompany'sfounder,saiditwouldnowmerelycompletethetwomostadvanceddrugtrials.



MaleimpotencepillsincludingViagraworkbywideningbloodvesselstoincreasethebloodflowneededforanerection.PfizerdroppedtestsofViagrainfemalesin2004afterstudiesfailedtoshowithelpedwomen.



TheflibanserinsetbackwasincontrasttoBoehringer'ssuccessinpioneeringanewbloodthinningpillforamarketthatrivalBayersaidcouldbeworth$15billion.



AU.S.advisorypanellastmonthrecommendclearanceofBoehringer'sPradaxapillforpreventingstrokesinpatientswithatypeofirregularheartbeat.

GOP Senator: Health Care Law Will Permit Sex Offenders to Get Viagra



The Congressional Research Service has confirmed Sen. Tom Coburn's assertions that sex offenders not in prison could get Viagra and other drugs treating erectile dysfunction under health plans subsidized by taxpayer dollars. (AP)


AP


The Congressional Research Service has confirmed Sen. Tom Coburn's assertions that sex offenders not in prison could get Viagra and other drugs treating erectile dysfunction under health plans subsidized by taxpayer dollars. (AP)



Sen. Tom Coburn drew ridicule last month for trying in vain to prohibit sex offenders from getting Viagra prescriptions under the new health care law.



But Coburn is now having the last laugh after the Congressional Research Service confirmed his assertions that sex offenders not in prison could get Viagra and other drugs treating erectile dysfunction under health plans subsidized by taxpayer dollars.



In a memo to the Oklahoma Republican, who is one of two doctors in the chamber, and provided to FoxNews.com, the CRS said there are no provisions in the new health care law "which would require health plans to limit the type of benefits that can be offered based on the plan beneficiary's prior criminal convictions."



"Additionally, there do not appear to be any provisions that would specifically restrict qualified health plans' coverage of drugs prescribed to treat ED," the memo read.



"Therefore, a convicted rapist, child molester, or other sex offender who is not incarcerated would not appear to be excluded from enrolling in a qualified health plan through an American Health Benefit Exchange in their state solely because of that conviction," the memo added.



Coburn offered an amendment blocking this to the companion bill that reshaped parts of the health care law. Sen. Dick Durbin, D-Ill., dismissed it as a "gotcha amendment" designed to be difficult for Democrats to oppose. But the amendment failed 57-42.



The CRS is also seeking information from the Department of Health and Human Servicers congressional liaison office per Coburn's request on whether there have been known cases in which federal health programs such as Medicaid provided sex offenders coverage for drugs to treat erectile dysfunction.



But the CRS sent Coburn news articles that describe cases in which sex offenders did receive those drugs through state Medicaid programs.

Wednesday, March 16, 2011

Despite facing budget cuts and layoffs, Milwaukee teachers fight for taxpayer-funded Viagra


MADISON, Wis. With the district in a financial crisis and hundreds of its members facing layoffs, the Milwaukee teachers union is taking a peculiar stand: fighting to get its taxpayer-funded Viagra back.


The union has asked a judge to order the school board to again include Pfizer Inc.'s erectile dysfunction drug and similar pills in its health insurance plans.


The filing is the latest in a two-year legal campaign in which the union has argued, so far unsuccessfully, that the board's policy of excluding erectile dysfunction drugs discriminates against male employees. The union says Viagra, Cialis, Levitra and others are necessary treatment for "an exclusively gender-related condition."


But lawyers for the school board say the drugs were excluded in 2005 to save money, and there is no discrimination because they are used primarily for recreational sex and not out of medical necessity.


The filing last month comes as the union, the Milwaukee Teachers' Education Association, is also protesting hundreds of layoff notices issued to teachers for the coming school year. Citing a "financial crisis" caused by exploding benefit costs and revenue shortfalls, the district's outgoing superintendent proposed laying off 682 employees in April.


The district gave layoff notices to 482 teachers in June, but recalled 89 of them last month. Additional teachers may be called back, but these are still the first layoffs of Milwaukee teachers in decades.


At least one lawmaker questioned why the union is fighting for Viagra while teachers are losing their jobs. A consultant for the school board has estimated that reinstating the drug benefit would cost $786,000 per year the cost to keep perhaps a dozen first-year teachers employed.


State Rep. Jason Fields argues that the money could be better spent any number of ways including saving jobs.


"You've got to be kidding me," said Fields, a Milwaukee Democrat. "The fact that is the point of contention is kind of frightening. What are our priorities? I'm all for love and peace. But almost 1 million dollars? And you go to court over this issue?"


Union spokeswoman Kris Collett declined comment. But its lawyer Barbara Quindel said the case was worth fighting despite the district's grim finances. Quindel said erectile dysfunction is associated with heart disease, prostate cancer and other conditions, and the drugs are approved by the Food and Drug Administration and recommended by the American Urological Association.


"MTEA believes that men should not be discriminated against in receiving treatment for their medical conditions," she said.


The union has argued the costs are tiny compared to the $1.3 billion annual budget. But the school board says they are "particularly burdensome" when it is under pressure to reduce benefit costs.


That the pills which can cost $20 apiece without insurance were included in the first place is somewhat unusual. Health insurer Aetna Inc., which provides one of the district's two plans, says its standard pharmacy plans exclude Viagra and other "drugs for lifestyle enhancement or performance."


Basic state employee health plans also generally don't cover those drugs, but more expensive premium plans might, said Dick Cauchi, who tracks health benefits at the National Conference of State Legislatures. Lisa Soronen, National School Boards Association senior staff attorney, also said she had never heard of a similar case or an example of a union negotiating coverage for erectile dysfunction drugs.


"If you are getting down to what drugs are covered, you are really getting in the weeds," she said, explaining most negotiations are over premiums and co-payments.


Board and union negotiators reached a deal in 2002 to cover six tablets per month for erectile dysfunction drugs in health plans that insure 10,000 employees, dependents and retirees. They quickly became popular.


By 2004, the number of claimants receiving prescriptions skyrocketed to more than 1,000 per year, costing the district $207,000. During negotiations in 2005, the board proposed eliminating the benefit and an arbitrator adopted the plan.


The union in 2008 filed a sex discrimination complaint with the state. In June, the Labor and Industry Review Commission ruled the union couldn't pursue the case without identifying employees who have been injured by the policy and the complaint was filed after the statute of limitations expired.


The union is asking a Milwaukee County Circuit Court judge to overturn that decision and declare the policy violates the Wisconsin Fair Employment Act. A ruling isn't expected for months.


Viagra is usually on the other side in discrimination cases. In recent years, several lawsuits have claimed that employer health plans discriminate against women when they cover Viagra but not contraceptives or infertility treatment.


But the Milwaukee union says males are treated unfairly here. In one brief, its lawyers argued that vaginal cream, anti-bacterial medicine and estrogen replacement medication for female sexual dysfunction are covered. Other options such as penile pumps and implants included in the plans "are far less desirable than oral medication," the filing said.


District spokesman Philip Harris said school officials won't comment because "we just want to leave it alone." But Miriam Horwitz, an attorney representing the board, argued in court filings the drugs weren't necessary to treat life-threatening disease or have children.

Tuesday, March 15, 2011

What Dems Must Do If They Want to Hold the Senate


Withjustamonthleftbeforethemidtermelections,andwiththeRepublicansleadingbysixpointsinRasmussenReports’GenericCongressionalBallot,ithasbecomeincreasinglyclearthatdissatisfactionwiththeDemocratsisgoingtoresultinaswingtotheRepublicansthisfall.



WhileitseemsalmostcertainthattheRepublicanswilltakecontroloftheHouse,theDemocratscanstillholdtheSenate.



TheGOPneedstenseatstotakecontroloftheSenate,andtheyarelikelytopickupsevenoreightseatsatthispoint.Thus,itappearsthatcontroloftheSenatewillcomedowntothreeorfourracesinthebluestatesofCalifornia,Washington,Connecticutandtoalesserextent,NewYork.TomaintaincontroloftheSenate,thePartymustputallofitsresourcesintheseraces.



InWashingtonState,DemocratPattyMurray’sadvantageoverRepublicanDinoRossiisthatshe’srunninginastatethathasconsistentlygoneDemocraticinstatewideelectionsthankstoSeattle’sliberal-leaningKingCounty.



However,whileMurrayhasaboutafive-pointleadoverRossiaccordingtotheRealClearPoliticsAverage,RasmussenReports’mostrecentpollhasMurraytrailingbyonepoint,47%to48%.



Towin,Murraymuststeerawayfromherliberalvotingrecordandemphasizetheneedforfiscalrestraint,balancingthebudgetandreducingspending.MurrayhascriticizedRossiforsayingheopposedthenewWallStreetregulations;sheshouldcontinuetodoso,andemphasizehisstrongtiestocorporatelobbyistsandspecialinterests,andhisveryconservativepositionsongayrights,theenvironmentandwomen’srights.



CaliforniahasalsobeenatraditionallyDemocraticstate,withevenmoreDemocratsthanusualwinningin2006and2008asthesubprimemortgagecrisisbatteredthestate.SenatorBarbaraBoxer’sstrongwinin2004andObama’s61%to37%wininCaliforniain2008ledmosttoassumeshewouldberelativelysafein2010.



However,thebadeconomyhascausedthestate’svoterstoturnontheDemocrats.Boxer’sweakestsupportisintheInlandEmpireandCentralValley,theareashithardestbythesubprimemeltdown.Further,Boxer’sliberalvotingrecordputsheratoddswiththecurrentsentimentsofthevoters.AsofJuly,herfavorabilityhaddroppedto42%,with48%unfavorable.



Justrecentlyasmid-September,theRealClearPoliticsAveragehadBoxerinadeadheatwithformerHewlett-PackardCEOCarlyFiorina.However,Boxer’sleadhasgrowninthepastfewweekstoaboutsevenpointsaheadofFiorina.



WhileBoxermaybemoreliberalthanvotersinCalifornia,Fiorinaismuchfarthertotherightthanthestate’spoliticalmainstream.BoxerneedstoemphasizeFiorina’sextremelyconservativepositionsonabortion,oildrilling,immigrationandguns,andarguethatsheistooextremeforCalifornia,particularlyforwomen.



BoxerparticularlyneedstocontinuetocalloutFiorina’soppositiontoabortionrights–notonlyhasBoxermadethisissuecentraltohercareer,butnoanti-abortioncandidatehaswonhighstatewideofficeinCaliforniainover20years.



Further,BoxermusttellFiorina’sstoryasthefailedCEOofHewlett-Packard:shefiredover30,000workersasCEOandshippedjobsoverseas,whilemaking$100millionandtakinga$21millionseverancepackagewhensheleft.Fiorina’sfailedbusinessexperiencegivesvotersnoreasontothinkshewouldbeagoodSenator.



ChrisDodd’sretirementinConnecticuthaslefthisseatopenforthefirsttimesince1974.TheDemocraticnominee,AttorneyGeneralRichardBlumenthal,hashadrelativelysolidpollingnumbers,buthisopponent,formerWWECEOLindaMcMahon,wonawell-runprimarycampaignthatemphasizedherexperienceasawomanturningasmallenterpriseintoamulti-billiondollarbusiness.



AsamoderateRepublicanrunningduringatimeofanti-Democraticsentiments,McMahonturnedthisintoacloserace.RasmussenReportshasBlumenthalleadingbyfivepoints,50%to45%,andtheQuinnipiacpollhasBlumenthal’sleadatthreepoints,49%to46%.



BlumenthalneedstomakethecasethatMcMahon’sbusinessisbuiltonhumansufferingandfailings.McMahondidnotprovidehealthcareforthewrestlers.Hundredsdiedofsteroidabuseandtherehasbeenwidespreaddrugaddiction.HerstoryisnottheAmericandream,butoneofhorrorandfailure..



Finally,inNewYork,DemocratKirstenGillibrandhasheldontoaleadoverRepublicanJoeDioGuardi,althoughasmallerleadthanwhatistypicalfromaDemocratinaNewYorkSenaterace.TheRealClearPoliticsAveragehasherleadingbyalmost11points,butthelatestpollfromSurveyUSAshowsheraheadbyjustonepoint,45%to44%.



Gillibrandwasabletoavoidanyseriousprimarychallengers,thankstoherbackingbytheDemocraticestablishment,buthercandidacyisnotparticularlystrongandshehasvulnerabilities.Tomakesureshewins,shewillneedthecontinuedsupportoftheParty.



Mostly,however,whatthePartyneedstowinisanationalmessageoffiscalprudenceanddisciplinetohelpgivethesefourkeyDemocratsthecovernecessarytowintheirraces.ThePartymustadvocateabold,centristagendathatfocusesonfiscaldisciplineandfiscalstimulusinitiativesthattargettheprivatesectorandencourageentrepreneurshipandjobcreation.Theymustberesponsivetovoters’desirestocurbspendingandtaxation,andreducethedeficitandthedebt.Ifnot,theSenatecouldfalltotheRepublicanstoo.



DouglasE.Schoenisapoliticalstrategist,FoxNewscontributorandauthorofthenewbook"MadasHell:HowtheTeaPartyMovementisFundamentallyRemakingOurTwo-PartySystem"publishedbyHarper,animprintofHarperCollins.



FollowFoxNewsOpiniononFacebookandTwitter!

EXCLUSIVE: Anne Hathaway "Mortified" Being Nude in Front Of Jake Gyllenhaal





In her latest drama “Love Other Drugs,” Anne Hathaway portrays free-spirited Maggie Murdock, who suddenly finds herself under the “drug” of love when she is charmed by Viagra salesman Jamie Randall, played by Jake Gyllenhaal.



But getting hot and heavy wasn’t exactly an enjoyable experience for the 27-year-old starlet.



“It’s racy – very racy. I keep asking people if it is too sexy for them. However it is just part of the job,” Hathaway told Pop Tarts at the film’s Hollywood premiere last week. “That being said, it is intensely mortifying taking your clothes off in front of other people, but it is also intensely mortifying doing a lot of things in front of people and I’ve learned how to deal with that. Who knows if I will ever do it again, it depends on the material.”



And according to Gyllenhaal, it is as real as reel can be.



“The sex is portrayed in a real way, in an intimate way, and nobody is hiding behind anybody,” he said. “I think that that is hopefully what love is about and that is what these two characters do in this movie. I hope people would want to see that, and if not then we’re both naked – so..."



But luckily for Hathaway and Gyllenhaal, the “awkward” situation was softened a little by the fact they’ve gotten intimate on-screen together before.



“We had already had fake onscreen sex before in ‘Brokeback Mountain’ so it came naturally, we just had to do it again. But in all seriousness, it was very brave of Anne. I think women tend to be objectified more than men and she really does bare a lot, not only literally but figuratively. Her performance was incredible,” Gyllenhaal said. “But we’re friends and we understand the process of acting, and as a result of that we felt comfortable, even when it was awkward, and we try to joke about it. I try to be as respectful as possible, and if you are respectful on the set it makes it as dirty as it can be onscreen.”



And despite of Gyllenhaal’s A-list status, the folks in the Viagra world weren’t too warm when it came to giving characterization tips.



“It was an amazing world to learn about, primarily the sales in pharmaceuticals. I was fascinated to find out how hard it is to get into that world – to learn information from active people, particularly people selling from Viagra,” he added. “So often when you’re making a movie about something, (the real professionals) are like ‘come on in.’ That wasn’t the case for this movie, but it was fascinating. It took a while for people to open up – I didn’t know why there was so much secrecy."

Study on Acne Suicide Risk Fuels Debate Over Drugs







Peoplewithsevereacneareatincreasedriskofattemptingsuicide,scientistssaidonFridayinastudy,whichfuelsadebateaboutwhetheracnedrugssuchasRoche'sAccutanepromptsuicidalthoughts.



Swedishscientistsfoundpatientshadanadditionalsuicideriskforuptoayearaftertreatmentwithisotretinoin,thegenericversionofAccutane,whichiscommonlyprescribedforpeoplewithsevereacne.



"Amoreprobableinterpretationisthattheunderlyingsevereacnemaybestexplaintheraisedrisk,"theysaid,althoughtheycouldnotruleoutthatitmaybe"asaconsequenceofexposuretothedrug."



Accutane,whichSwissdrugmakerRochesaidlastyearitwouldstopsellingbecauseofgenericcompetition,hashadacontroversialhistorysinceits1982launch.



Whilepowerfulatclearingacne,thedrughasbeenlinkedtobirthdefectsiftakenduringpregnancyandhasalsobeensuspectedofcausingmentalsideeffects,althoughRochehasvigorouslydefendedpersonalinjuryclaimsinthisarea.



ItisnowavailableasgenericisotretinoinandsoldbydrugmakersincludingMylan,RanbaxyandTevaPharmaceuticalIndustries.



Acneisawidespreadskincomplaintfoundinupto80percentofadolescents.Whilemostcasesaremild,moreseverecasescanbequitedisfiguring,asensitiveprobleminsocialgroupsoftenalreadyselfconsciousabouttheirbodies.



Doctorssayisotretinoiniseffectiveinpatientswithsevereacne,butalsonotereportslinkingisotretinointodepressionandsuicidalbehavior.Scientificstudieshavehadconflictingresults.



AstudybyCanadianscientistspublishedintheJournalofClinicalPsychiatryin2008suggestedisotretinoinmightdoubletheriskofdevelopingdepression.



ANorwegianstudyearlierthisyearfoundthatlevelsofdepressionandsuicidalthoughtsweretwoorthreetimeshigherinyoungpeoplewhohadthemostsevereacnethaninthosewithoutit,suggestingthedrugtreatmentmaynotbetoblame.



NaturalCourse?

Againstthisbackground,AndersSundstromandateamfromtheKarolinskaInstituteinSwedeninvestigatedsuicideattemptsbefore,duringandafterisotretinointreatmentforsevereacne.



Theyassesseddatafrom5,756peoplewhohadbeenprescribedisotretinoinfrom1980-89andlinkedthesetohospitaldischargeandcauseofdeathregistersfrom1980-2001.



Theresults,publishedintheBritishMedicalJournal,found128patientsadmittedtohospitalafterasuicideattempt.Thestudyalsofoundthenumberofsuicideattemptsrosebetweenoneandthreeyearsbeforestartingtotakeisotretinoin.



Theriskswerehighestwithinsixmonthsoftreatmentending.



Sundstrom'steamsaiditwasimpossibletosayforcertainwhetherthecontinuedriseinsuicideriskwas"duetothenaturalcourseofsevereacne,ortonegativeeffectsofthetreatment."



Commentingonthestudy,SarahBaileyofthepharmacyandpharmacologydepartmentatBritain'sBathUniversitysaiditwasimportantresearchwhichstrengthenstheviewthatacneitselfcanhavesignificantpsychologicaleffects.



"Thecontroversialissueofincreasedsuicideriskwithisotretinoinuseisnotresolvedbythispaper,"shesaid,addingthatthemostinterestingfindingwasthattheriskofsuicideisincreasedaftertreatment,showingthatitis"essentialtocontinuetomonitorpatientscarefully."